CORRESP Filing
Aptevo Therapeutics Inc.
Date: May 21, 2025 · CIK: 0001671584 · Accession: 0000950170-25-075622
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-287244
Letter
May 21, 2025 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attention: Mr. Alan Campbell Re: Aptevo Therapeutics Inc. Registration Statement on Form S-1 Filed May 13, 2025 File No. 333-287244 Dear Mr. Campbell: In accordance with Rule 461 under the Securities Act of 1933, as amended, we hereby request acceleration of the effective date of the Registration Statement on Form S-1 (File No. 333-287244) of Aptevo Therapeutics Inc. (the “Registration Statement”). We respectfully request that the Registration Statement become effective as of 4:30 p.m., Eastern Time, on May 22, 2025, or as soon as practicable thereafter. Once the Registration Statement has been declared effective, please confirm that event with our counsel, Paul Hastings LLP, by calling Sean M. Donahue at (202) 551-1704. Very truly yours, Aptevo Therapeutics Inc. By: /s/ Marvin L. White Marvin L. White President and Chief Executive Officer
CC: SoYoung Kwon, Aptevo Therapeutics Inc. Daphne Taylor, Aptevo Therapeutics Inc. Sean M. Donahue, Paul Hastings LLP
Show Raw Text
CORRESP 1 filename1.htm CORRESP May 21, 2025 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attention: Mr. Alan Campbell Re: Aptevo Therapeutics Inc. Registration Statement on Form S-1 Filed May 13, 2025 File No. 333-287244 Dear Mr. Campbell: In accordance with Rule 461 under the Securities Act of 1933, as amended, we hereby request acceleration of the effective date of the Registration Statement on Form S-1 (File No. 333-287244) of Aptevo Therapeutics Inc. (the “Registration Statement”). We respectfully request that the Registration Statement become effective as of 4:30 p.m., Eastern Time, on May 22, 2025, or as soon as practicable thereafter. Once the Registration Statement has been declared effective, please confirm that event with our counsel, Paul Hastings LLP, by calling Sean M. Donahue at (202) 551-1704. Very truly yours, Aptevo Therapeutics Inc. By: /s/ Marvin L. White Marvin L. White President and Chief Executive Officer CC: SoYoung Kwon, Aptevo Therapeutics Inc. Daphne Taylor, Aptevo Therapeutics Inc. Sean M. Donahue, Paul Hastings LLP